Boyd KD - Search Results

1

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.

Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Dickens NJ, et al. Among authors: boyd kd. Clin Cancer Res. 2010 Mar 15;16(6):1856-64. doi: 10.1158/1078-0432.CCR-09-2831. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215539 Free PMC article. Clinical Trial.

2

Liposomal cytarabine in cerebrospinal fluid.

Boyd K, Jenner M, Treleaven J, Kenny J, Rhoades E. Boyd K, et al. Br J Haematol. 2009 Jun;145(6):679. doi: 10.1111/j.1365-2141.2008.07518.x. Epub 2008 Dec 8. Br J Haematol. 2009. PMID: 19076172 Free article. No abstract available.

3

The impact of extramedullary disease at presentation on the outcome of myeloma.

Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE, Morgan GJ. Wu P, et al. Leuk Lymphoma. 2009 Feb;50(2):230-5. doi: 10.1080/10428190802657751. Leuk Lymphoma. 2009. PMID: 19197724

4

The potential role of epigenetic therapy in multiple myeloma.

Smith EM, Boyd K, Davies FE. Smith EM, et al. Br J Haematol. 2010 Mar;148(5):702-13. doi: 10.1111/j.1365-2141.2009.07976.x. Epub 2009 Nov 13. Br J Haematol. 2010. PMID: 19912222 Free article. Review.

5

XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.

Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. Bagratuni T, et al. Blood. 2010 Jul 15;116(2):250-3. doi: 10.1182/blood-2010-01-263236. Epub 2010 Apr 26. Blood. 2010. PMID: 20421453 Free article. Clinical Trial.

6

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. Schey SA, et al. Br J Haematol. 2010 Aug;150(3):326-33. doi: 10.1111/j.1365-2141.2010.08250.x. Epub 2010 Jun 10. Br J Haematol. 2010. PMID: 20553268 Free article. Clinical Trial.

7

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. Walker BA, et al. Among authors: boyd kd. Blood. 2010 Oct 14;116(15):e56-65. doi: 10.1182/blood-2010-04-279596. Epub 2010 Jul 8. Blood. 2010. PMID: 20616218 Free article. Clinical Trial.

8

High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.

Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, Morgan GJ. Boyd KD, et al. Leuk Lymphoma. 2010 Nov;51(11):2126-9. doi: 10.3109/10428194.2010.509893. Epub 2010 Sep 21. Leuk Lymphoma. 2010. PMID: 20858096 No abstract available.

9

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Walker BA, et al. Among authors: boyd kd. Blood. 2011 Jan 13;117(2):553-62. doi: 10.1182/blood-2010-04-279539. Epub 2010 Oct 13. Blood. 2011. PMID: 20944071 Free article. Clinical Trial.

10

Novel drugs in myeloma: harnessing tumour biology to treat myeloma.

Boyd KD, Davies FE, Morgan GJ. Boyd KD, et al. Recent Results Cancer Res. 2011;183:151-87. doi: 10.1007/978-3-540-85772-3_8. Recent Results Cancer Res. 2011. PMID: 21509685 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters